Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3534-3534
◽
Keyword(s):
Phase Ii
◽